Antiamoebic drugs for treating amoebic colitis - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

Batra 1972 (Continued) Not included in this review: number of hours from start of treatment to reduction in diarrhoea, tenesmus, and bloody stools; disappearance of colonic ulcers on sigmoidoscopic examination on day 5 and day 11 of treatment Notes Location: hospital in New Delhi, India Date: 1972 (date of publication only; actual study period not reported) Source of funding: Merck, Sharp and Dohme Botero 1974 Methods Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: unclear; reported as “double-blind”, but blinding of participants, care provider, and outcome assessors not described Inclusion of all randomized participants: 95.8% (115/120) Participants Number: 120 enrolled; 115 analysed; 5 lost to follow up; 1 participant in the Ro 7-0207 terminated treatment after day 6 because of adverse effects Inclusion criteria: adult males with clinical symptoms of intestinal amoebiasis and confirmed by the presence of E. histolytica in the stools examined by direct and Ritchie formalin-ether concentration methods Exclusion criteria: not stated Interventions 1. Ro 7-0207 (ornidazole): 2 x 250 mg capsules twice daily for 10 days 2. Metronidazole: 2 x 250 mg capsules twice daily for 10 days Outcomes 1. Parasitological response: clearance of E. histolytica from stools at the end of treatment and on at weekly intervals on follow up for at least 1 month 2. Relapse: reappearance of E. histolytica in the stools within 1 month after becoming negative at the end of treatment 3. Clinical response: disappearance or improvement of clinical signs and symptoms on day 5, at the end of treatment, and at weekly intervals during follow up for at least 1 month 4. Adverse events: clinical adverse events monitored for all participants but cardiovascular, neurological, and laboratory monitoring only for the first 20 participants (laboratory tests not specified) Notes Location: hospital in Medellin, Colombia Date: 1974 (date of publication only; actual study period not reported) Source of funding: not stated Botero 1977 Methods Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: unclear; reported as “double-blind”, but blinding of participants, care provider, and outcome assessors not described Inclusion of all randomized participants: 100% Participants Number: 100 enrolled and 100 analysed Inclusion criteria: adult males with clinical symptoms of intestinal amoebiasis and stools positive for E. histolytica examined by direct and Ritchie formalin-ether concentration methods Antiamoebic drugs for treating amoebic colitis (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 35
Botero 1977 (Continued) Exclusion criteria: not stated Concomitant intestinal infection: 26 participants in panidazole group and 27 participants in metronidazole group had concomitant infection with other enteric protozoa and intestinal helminths (Entamoeba coli, Endolimax nana, Iodamoeba butschlii, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, Strongyloides stercoralis) Interventions 1. Panidazole: 2 x 250 mg tablets (500 mg), 4 times daily for 6 days 2. Metronidazole: 2 x 250 mg tablets (500 mg), 4 times daily for 6 days Outcomes 1. Parasitological cure: eradication of parasites in any of the post-treatment laboratory examinations 2. Clinical response: improvement or disappearance of symptoms during weekly follow up for 4 weeks after treatment 3. Adverse events: clinical adverse events monitored during treatment and on follow up; laboratory tests monitored before and after treatment including complete blood count, erythrocyte sedimentation rate, blood urea nitrogen, liver transaminases, urinalysis, and electrocardiogram Not included in this review: number of stools passed in 24 hours on day 3 and day 6 of treatment and on days 7 and 21 after treatment; clearance of E. histolytica in asymptomatic carriers Notes Location: Colombia Date: 1977 (date of publication only; actual study period not reported) Source of funding: not stated Chunge 1989 Methods Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: double (only participants and laboratory staff examining stools were blinded) Inclusion of all randomized participants: unclear; only those who completed the required stool examinations were included (225 participants)and number randomized not stated Participants Number: number enrolled and randomized not stated, 225 analysed Inclusion criteria: adults and children presenting with at least any 4 of the following symptoms of intestinal amoebiasis: abdominal pain, diarrhoea, constipation, mucoid stools, malaise, flatulence, nausea, fever, tenesmus, and stool specimens positive for trophozoites or cysts of E. histolytica by direct smear or formol-ether concentration technique Exclusion criteria: pregnant women Interventions 1. Tinidazole (Fasigyn): 2 g single oral dose daily for 3 days 2. Tinidazole (Tynazole): 2 g single oral dose daily for 3 days 3. Metronidazole (Flagyl): 400 mg thrice daily orally for 5 days 4. Metronidazole (Metrozol): 400 mg thrice daily orally for 5 days Outcomes 1. Parasitological cure: absence of trophozoites or cysts from stool specimens on day 6 after start of treatment 2. Clinical cure: absence of any 4 of the symptoms initially present at day 6 after start of treatment Notes Location: outpatient departments of 3 district hospitals in Kiambo, Kilifi, and Machakos in Kenya Date: 1989 (date of publication only; actual study period not reported) Source of funding: Farmitalia Carlo Erba Antiamoebic drugs for treating amoebic colitis (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 36
Page 1 and 2: Antiamoebic drugs for treating amoe
Page 3 and 4: Analysis 6.4. Comparison 6 Subgroup
Page 5 and 6: Authors’ conclusions Tinidazole i
Page 7 and 8: parasite RNA and DNA (Haque 1995; H
Page 9 and 10: histopathology. We included individ
Page 11 and 12: sponsored trials were conducted wit
Page 13 and 14: (WHO 1969) where ’cure’ was def
Page 15 and 16: Figure 1. Alternative drug vs metro
Page 17 and 18: ness or nausea. No abnormalities in
Page 19 and 20: 4.1. Single-dose secnidazole versus
Page 21 and 22: with some activity against cysts in
Page 23 and 24: A U T H O R S ’ C O N C L U S I O
Page 25 and 26: suspension (two days dosage) in the
Page 27 and 28: el tratamiento de ninos con amibias
Page 29 and 30: Murray 1980 {published data only} M
Page 31 and 32: Sankale 1969 {published data only}
Page 33 and 34: Dans 2006 Dans L, Martinez E. Amoeb
Page 35 and 36: associated with increased expressio
Page 37: Awal 1979 (Continued) Participants
Page 41 and 42: Donckaster 1964 (Continued) and adu
Page 43 and 44: Kapadia 1968 Methods Generation of
Page 45 and 46: Mathur 1976 (Continued) Outcomes 1.
Page 47 and 48: Misra 1978 (Continued) 3. Adverse e
Page 49 and 50: Nnochiri 1967 (Continued) haemoglob
Page 51 and 52: Panggabean 1980 (Continued) Interve
Page 53 and 54: Prasad 1985 (Continued) years of ag
Page 55 and 56: Rossignol 2007 (Continued) Interven
Page 57 and 58: Singh 1977 (Continued) Outcomes 1.
Page 59 and 60: Swami 1977 (Continued) SGPT), and b
Page 61 and 62: (Continued) Baranski 1966 Not RCT B
Page 63 and 64: (Continued) Huggins 1969 Not RCT Hu
Page 65 and 66: (Continued) Padilla 2002 Interventi
Page 67 and 68: (Continued) Simjee 1985 Study popul
Page 69 and 70: Characteristics of studies awaiting
Page 71 and 72: 2 Parasitological failure: 1 to 14
Page 73 and 74: 2.3 Chlorhydroxyquinoline vs diiodo
Page 75 and 76: Comparison 9. Subgroup analyses: an
Page 77 and 78: (... Continued) Study or subgroup A
Page 79 and 80: Analysis 1.4. Comparison 1 Alternat
Page 81 and 82: Analysis 1.6. Comparison 1 Alternat
Page 83 and 84: Analysis 2.2. Comparison 2 Any anti
Page 85 and 86: Analysis 3.2. Comparison 3 Combinat
Page 87 and 88: Analysis 5.1. Comparison 5 Other an
Page 89 and 90:
Analysis 6.1. Comparison 6 Subgroup
Page 91 and 92:
(... Continued) Study or subgroup A
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
(Continued) 24 - - chloroquine oxyt
Page 103 and 104:
(Continued) Department of Medicine,
Page 105 and 106:
(Continued) Africa Egypt Rossignol
Page 107 and 108:
(Continued) Stool microscopy plus s
Page 109 and 110:
(Continued) 6. Not used, but mentio
Page 111 and 112:
(Continued) Padilla 2000 Adequate U
Page 113 and 114:
(Continued) Misra 1974 Malaise: tin
Page 115 and 116:
(Continued) Pehrson 1984 ticipants)
Page 117 and 118:
(Continued) ; metronidazole (4 part
Page 119 and 120:
(Continued) Panidazole Botero 1977
Page 121 and 122:
(Continued) Appendix 12. Adverse ev
Page 123 and 124:
(Continued) Rossignol 2001 Rossigno
Page 125 and 126:
(Continued) Secnidazole vs quinfami
Page 127 and 128:
(Continued) idazole was encountered
Page 129 and 130:
(Continued) Combinationtinidazole a
Page 131 and 132:
(Continued) H I S T O R Y Protocol
Page 133:
Sensitivity analyses We intended to
show all

Antiamoebic drugs for treating amoebic colitis - The Cochrane Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?